Pfizer has attributed Hospira’s sterile injectables and biosimilar assets to its return to growth, offsetting 17 quarters of declining sales.
Germany's Merck has upped bioreactor capacity at its facility in Martillac, France in an investment it says broadens its biologics manufacturing offering.
The new entity will focus on a haemophilia pipeline utilising the XTEN half-life extension technology, bispecific antibodies and gene therapies.
Plans to reshape its manufacturing network will include increasing biologics capacity beyond its recent acquisitions and expansions, says AstraZeneca.
Samsung Biologics has been contracted by its joint venture entity Samsung Bioepis to manufacturer biosimilars from its facility in Korea.
Shire will retain Baxalta’s biologics expertise and continue assessing its manufacturing network following the completion of its $32bn acquisition, expected next month.